Drug Patents owned by Takeda Pharms Usa
1. List of Actoplus Met drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101660 | TAKEDA PHARMS USA | Solid preparation |
Jan, 2027
(3 years from now) | |
| US9320714 | TAKEDA PHARMS USA | Tablet |
Feb, 2029
(5 years from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Treatment: NA
Dosage: TABLET;ORAL
ACTOPLUS MET family patents
7
Japan
4
United States
2
Korea, Republic of
2
Canada
2
New Zealand
2
Spain
2
Portugal
2
European Union
1
Colombia
1
Australia
1
Israel
1
Denmark
1
Costa Rica
1
Cyprus
1
Ukraine
1
Russia
1
Poland
1
Morocco
1
Norway
1
Hong Kong
1
Slovenia
1
Mexico
1
Brazil
1
China
1
South Africa
2. List of Actoplus Met Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9060941 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(3 months from now) | |
| US8668931 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(3 months from now) | |
| US8470368 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(3 months from now) | |
| US7785627 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(3 years from now) | |
| US7959946 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(3 years from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ACTOPLUS MET XR family patents
17
United States
7
Korea, Republic of
6
Japan
5
China
4
Australia
4
European Union
3
Canada
3
New Zealand
3
Spain
3
Hong Kong
2
Brazil
2
Taiwan
1
EA
1
Israel
1
Peru
1
Malaysia
1
Costa Rica
1
Singapore
1
Ukraine
1
Morocco
1
Norway
1
Mexico
1
Georgia
1
Argentina
1
South Africa
3. List of Alunbrig drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9012462 | TAKEDA PHARMS USA | Phosphorous derivatives as kinase inhibitors |
Apr, 2031
(7 years from now) | |
| US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9273077 | TAKEDA PHARMS USA | Phosphorus derivatives as kinase inhibitors |
May, 2029
(5 years from now) | |
| US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 22, 2027 |
| New Indication (I) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
ALUNBRIG family patents
22
United States
9
Japan
5
Korea, Republic of
4
Israel
4
China
4
European Union
3
Mexico
3
Hungary
3
Lithuania
2
Australia
2
EA
2
Croatia
2
Canada
2
Denmark
2
Spain
2
Portugal
2
Norway
2
Slovenia
1
Colombia
1
Ecuador
1
Luxembourg
1
Dominican Republic
1
Netherlands
1
New Zealand
1
Tunisia
1
Peru
1
Costa Rica
1
Chile
1
Cyprus
1
Singapore
1
Ukraine
1
Philippines
1
Poland
1
Hong Kong
1
Brazil
1
South Africa
1
RS
4. List of Colcrys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7981938 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US7964647 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US8093297 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(5 years from now) | |
| US8097655 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US8415396 | TAKEDA PHARMS USA | Colchine compositions and methods |
Oct, 2028
(5 years from now) | |
| US7964648 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(5 years from now) | |
| US8093296 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US8093298 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(5 years from now) | |
| US8415395 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(5 years from now) | |
| US7619004 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(5 years from now) | |
| US7935731 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(5 years from now) | |
| US7601758 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares |
Feb, 2029
(5 years from now) | |
| US7906519 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(5 years from now) | |
| US8440721 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(5 years from now) | |
| US7915269 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(5 years from now) | |
| US7820681 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(5 years from now) | |
| US8440722 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(5 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 29 July, 2009
Treatment: A method for treatment of gout flares during prophylaxis; Method of treating gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; Method of us...
Dosage: TABLET;ORAL
COLCRYS family patents
32
United States
5. List of Dexilant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(4 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(a month from now) | |
| US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(4 months from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(4 months from now) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 months from now) | |
|
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 months from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(2 years from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(3 years from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(3 years from now) | |
|
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(3 years from now) | |
|
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(6 years from now) | |
|
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(7 years from now) | |
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(8 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); To maintain healing of ee and relief of heartburn; For healing of all grades of erosive esophagi...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
35
United States
23
Japan
12
European Union
9
Korea, Republic of
8
Canada
7
Spain
7
Argentina
6
China
5
Australia
5
Denmark
5
Cyprus
5
Portugal
5
Brazil
4
Malaysia
4
Hong Kong
4
Mexico
4
Taiwan
3
Israel
3
New Zealand
3
Peru
3
Costa Rica
3
Russia
3
Poland
3
Norway
2
Singapore
2
Slovenia
2
South Africa
1
Colombia
1
OA
1
Austria
1
Chile
1
Morocco
1
Germany
1
Hungary
1
Belgium
6. List of Dexilant Solutab drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(4 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(a month from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(4 months from now) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 months from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(2 years from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
|
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(5 years from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(5 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB family patents
30
United States
21
Japan
10
European Union
8
Argentina
7
Korea, Republic of
7
Canada
5
Australia
5
Spain
5
Peru
5
Brazil
5
China
5
Taiwan
4
New Zealand
4
Malaysia
4
Costa Rica
4
Mexico
3
Denmark
3
Cyprus
3
Portugal
3
Poland
3
Norway
3
Hong Kong
3
South Africa
2
Israel
2
Chile
2
Morocco
2
Slovenia
1
Colombia
1
Ecuador
1
EA
1
Dominican Republic
1
OA
1
Uruguay
1
Tunisia
1
Austria
1
Singapore
1
Ukraine
1
Germany
1
Georgia
1
Hungary
1
Belgium
7. List of Duetact drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700128 | TAKEDA PHARMS USA | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
Jan, 2027
(3 years from now) | |
| US8071130 | TAKEDA PHARMS USA | Solid preparation |
Jun, 2028
(5 years from now) | |
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET;ORAL
DUETACT family patents
6
Japan
3
Korea, Republic of
2
Australia
2
Croatia
2
Canada
2
New Zealand
2
Spain
2
Peru
2
Russia
2
Morocco
2
Norway
2
Georgia
2
Argentina
2
Brazil
2
China
2
South Africa
2
United States
2
Taiwan
2
European Union
1
Israel
1
Denmark
1
Malaysia
1
Costa Rica
1
Cyprus
1
Jordan
1
Portugal
1
Ukraine
1
Poland
1
Slovenia
1
Mexico
1
Hungary
8. List of Exkivity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9796712 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) | |
| US10227342 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 15, 2026 |
| Orphan Drug Exclusivity (ODE) | Sep 15, 2028 |
Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient
NCE-1 date: 2025-09-15
Market Authorisation Date: 15 September, 2021
Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...
Dosage: CAPSULE;ORAL
EXKIVITY family patents
6
United States
4
Japan
3
European Union
2
Australia
2
Israel
2
Korea, Republic of
2
New Zealand
2
Chile
2
Singapore
2
Morocco
2
Georgia
2
China
1
Colombia
1
Ecuador
1
EA
1
Croatia
1
Canada
1
Denmark
1
Spain
1
Tunisia
1
Peru
1
Saudi Arabia
1
Costa Rica
1
ME
1
Cyprus
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Slovenia
1
Mexico
1
Brazil
1
South Africa
1
RS
1
Cuba
1
Hungary
1
Turkey
1
Lithuania
9. List of Fosrenol drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(1 year, 2 months from now) | |
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 2 months from now) | |
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(7 years from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(7 years from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 24 September, 2014
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Dosage: POWDER;ORAL
FOSRENOL family patents
14
United States
7
Japan
6
European Union
5
Denmark
4
Australia
4
Canada
4
Spain
4
Cyprus
4
Portugal
4
Poland
4
Slovenia
4
China
3
EA
3
Korea, Republic of
3
Brazil
2
Austria
2
Norway
2
Germany
2
South Africa
2
Hungary
1
Iceland
1
Israel
1
IB
1
New Zealand
1
Peru
1
Singapore
1
Czech Republic
1
Hong Kong
1
Mexico
1
Argentina
1
Finland
1
Taiwan
10. List of Iclusig drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8114874 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
Jan, 2027
(3 years from now) | |
| US9493470 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| US11192897 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| US11384086 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9029533 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US11192895 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 18, 2023 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 14 December, 2012
Treatment: A method of treating chronic myelogenous leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the ...
Dosage: TABLET;ORAL
ICLUSIG family patents
40
United States
8
Australia
8
Japan
8
China
6
Canada
6
European Union
5
Mexico
4
EA
4
Israel
3
Korea, Republic of
3
Spain
3
Brazil
2
Denmark
2
Portugal
2
Poland
2
Slovenia
2
Hungary
1
Luxembourg
1
New Zealand
1
Chile
1
Cyprus
1
Hong Kong
1
Lithuania
11. List of Intuniv drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6811794 | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Jul, 2022
(11 months ago) | |
|
US6811794 (Pediatric) | TAKEDA PHARMS USA | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
Jan, 2023
(5 months ago) | |
Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 September, 2009
Treatment: Treatment of attention-deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
INTUNIV family patents
1
United States
12. List of Kazano drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2025
(2 years from now) | |
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 9 months from now) | |
| US8900638 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and metformin hydrochloride |
May, 2029
(5 years from now) | |
Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL
KAZANO family patents
12
United States
9
China
7
Japan
3
Israel
3
Korea, Republic of
3
Argentina
3
Taiwan
2
Australia
2
EA
2
Canada
2
New Zealand
2
Spain
2
Peru
2
Malaysia
2
Costa Rica
2
Ukraine
2
Morocco
2
Norway
2
Georgia
2
Brazil
2
South Africa
2
European Union
1
Colombia
1
Ecuador
1
Luxembourg
1
Croatia
1
Dominican Republic
1
Netherlands
1
Denmark
1
Tunisia
1
Austria
1
Cyprus
1
Jordan
1
Portugal
1
Poland
1
Hong Kong
1
Slovenia
1
Germany
1
RS
1
Mexico
1
Hungary
13. List of Mydayis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6913768 | TAKEDA PHARMS USA | Sustained release delivery of amphetamine salts |
May, 2023
(13 days ago) | |
| US9173857 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
May, 2026
(2 years from now) | |
| US8846100 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
Aug, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Mar 13, 2023 |
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
MYDAYIS family patents
9
United States
1
Ecuador
1
AP
1
Iceland
1
Australia
1
EA
1
Israel
1
Croatia
1
Korea, Republic of
1
OA
1
Canada
1
New Zealand
1
Denmark
1
Spain
1
Costa Rica
1
Austria
1
Cyprus
1
Ukraine
1
Poland
1
Japan
1
Morocco
1
Norway
1
Hong Kong
1
Slovenia
1
Germany
1
Mexico
1
Brazil
1
China
1
South Africa
1
European Union
14. List of Nesina drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 9 months from now) | |
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Dec, 2025
(2 years from now) | |
| US8697125 | TAKEDA PHARMS USA | Tablet preparation without causing a tableting trouble |
Jun, 2029
(6 years from now) | |
Drugs and Companies using ALOGLIPTIN BENZOATE ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL
NESINA family patents
12
United States
8
China
6
Japan
3
Argentina
3
Taiwan
2
Israel
2
Croatia
2
Korea, Republic of
2
Canada
2
Spain
2
Norway
2
European Union
1
Luxembourg
1
Australia
1
EA
1
Netherlands
1
New Zealand
1
Denmark
1
Peru
1
Malaysia
1
Costa Rica
1
Austria
1
Chile
1
Cyprus
1
Portugal
1
Ukraine
1
Poland
1
Morocco
1
Hong Kong
1
Germany
1
Slovenia
1
Georgia
1
Brazil
1
South Africa
1
RS
1
Mexico
1
Hungary
15. List of Ninlaro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8546608 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(1 year, 2 months from now) | |
| US7687662 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
| US8530694 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
| US8003819 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
| US8859504 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(6 years from now) | |
| US7442830 | TAKEDA PHARMS USA | Proteasome inhibitors |
Nov, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233115 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(1 year, 2 months from now) | |
| US8871745 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(4 years from now) | |
| US9175017 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 20, 2022 |
Drugs and Companies using IXAZOMIB CITRATE ingredient
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
NINLARO family patents
47
United States
15
China
12
Korea, Republic of
12
Hong Kong
10
Japan
10
European Union
9
Israel
8
Taiwan
7
New Zealand
7
Argentina
6
EA
6
Peru
6
Brazil
6
South Africa
5
Mexico
4
Canada
4
Denmark
4
Spain
4
Malaysia
4
Portugal
4
Ukraine
4
Philippines
3
Ecuador
3
Australia
3
Croatia
3
Costa Rica
3
Cyprus
3
Singapore
3
Poland
3
Norway
3
Slovenia
3
Georgia
2
Chile
2
RS
1
Colombia
1
Iceland
1
Luxembourg
1
Dominican Republic
1
Netherlands
1
Tunisia
1
Austria
1
Morocco
1
Germany
1
Hungary
1
Lithuania
16. List of Omontys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(11 months from now) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(11 months from now) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(11 months from now) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(11 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(2 years from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(2 years from now) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS family patents
32
United States
9
Japan
6
Korea, Republic of
6
European Union
5
New Zealand
4
Australia
4
EA
4
Canada
4
Norway
4
Mexico
4
Brazil
4
China
4
South Africa
3
Iceland
2
Croatia
2
Denmark
2
Spain
2
Costa Rica
2
Cyprus
2
Singapore
2
Portugal
2
Ukraine
2
Poland
2
Hong Kong
2
Slovenia
1
AP
1
Israel
1
OA
1
Yugoslavia
1
Austria
1
ME
1
Morocco
1
Georgia
1
Germany
17. List of Oseni drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 9 months from now) | |
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(1 year, 9 months from now) | |
| US8637079 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and pioglitazone |
Jun, 2029
(5 years from now) | |
Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL
OSENI family patents
12
United States
9
China
6
Japan
4
Taiwan
3
Israel
3
Korea, Republic of
3
Argentina
2
Australia
2
EA
2
Croatia
2
Canada
2
New Zealand
2
Denmark
2
Spain
2
Malaysia
2
Costa Rica
2
Austria
2
Cyprus
2
Portugal
2
Ukraine
2
Poland
2
Morocco
2
Norway
2
Hong Kong
2
Germany
2
Mexico
2
Slovenia
2
Brazil
2
South Africa
2
RS
2
Georgia
2
European Union
1
Ecuador
1
Luxembourg
1
Dominican Republic
1
Netherlands
1
Tunisia
1
Peru
1
Chile
1
ME
1
Jordan
1
Hungary
18. List of Trintellix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7144884 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Jun, 2026
(3 years from now) | |
| US8722684 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8476279 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Oct, 2022
(8 months ago) | |
| US8969355 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US11458134 | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9125910 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9125909 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9125908 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9861630 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9227946 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| US9278096 | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Mar, 2032
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jan 22, 2024 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
Market Authorisation Date: 30 September, 2013
Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use of trintellix for the treatment of major depressive disorder (mdd) in adult...
Dosage: TABLET;ORAL
TRINTELLIX family patents
28
United States
12
Denmark
11
Japan
8
Brazil
7
Korea, Republic of
6
China
5
Spain
5
European Union
4
Australia
4
EA
4
Austria
4
Cyprus
4
Portugal
4
Ukraine
4
Poland
4
Norway
4
Hong Kong
4
Argentina
3
Croatia
3
Canada
3
New Zealand
3
Malaysia
3
Slovenia
3
Germany
3
Mexico
3
RS
3
Hungary
2
Colombia
2
Iceland
2
Israel
2
Chile
2
South Africa
2
Taiwan
1
Luxembourg
1
Egypt
1
Netherlands
1
Yugoslavia
1
Tunisia
1
ME
1
Morocco
1
Belgium
1
Lithuania
19. List of Uloric drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7361676 | TAKEDA PHARMS USA | Solid preparation containing single crystal form |
Mar, 2024
(9 months from now) | |
| US8372872 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(8 years from now) | |
| US9107912 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(8 years from now) | |
Drugs and Companies using FEBUXOSTAT ingredient
Market Authorisation Date: 13 February, 2009
Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline
Dosage: TABLET;ORAL
ULORIC family patents
6
United States
4
Japan
3
China
2
Canada
2
Australia
2
Spain
2
Korea, Republic of
2
European Union
1
Cyprus
1
Slovenia
1
Brazil
1
Denmark
1
Portugal
1
Russia
1
Hong Kong
20. List of Velcade drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6958319 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 4 months ago) | |
| US6713446 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 4 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6713446 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(10 months ago) | |
|
US6958319 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(10 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Apr 8, 2022 |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 13 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
VELCADE family patents
9
United States
4
European Union
3
Cyprus
3
Denmark
3
Spain
2
Canada
2
Portugal
2
Japan
1
Germany
1
Australia
1
Turkey
1
Austria
1
Hong Kong
21. List of Vyvanse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(3 months ago) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7671031 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7659254 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7105486 | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Feb, 2023
(3 months ago) | |
| US7662788 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7674774 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7678771 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7723305 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7713936 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7687466 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7223735 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(3 months ago) | |
| US7718619 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7678770 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7687467 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7671030 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7700561 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
|
US7678771 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7718619 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7223735 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(2 months from now) | |
|
US7655630 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7659253 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7662788 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7662787 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(2 months from now) | |
|
US7659254 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7671030 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7671031 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7674774 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7678770 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7687466 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7687467 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7713936 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7700561 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7105486 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Aug, 2023
(2 months from now) | |
|
US7723305 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 28 January, 2017
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults; Indicated for the treatment of attention-deficit/hyperacti...
Dosage: TABLET, CHEWABLE;ORAL
VYVANSE family patents
688
United States
18
Australia
15
European Union
13
Japan
11
Canada
9
Korea, Republic of
8
China
5
Austria
4
Israel
4
Spain
3
Mexico
3
Brazil
2
EA
2
New Zealand
2
Norway
2
Germany
2
South Africa
1
Egypt
1
Netherlands
1
Denmark
1
Cyprus
1
Singapore
1
Portugal
1
Russia
1
Poland
1
Hong Kong
1
Slovenia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic